At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 225 enrolled
Drug / intervention
13-valent pneumococcal conjugate vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jul 2, 2008·Updated Oct 25, 2011
In Brief
A Phase 3 clinical trial evaluating 13-valent pneumococcal conjugate vaccine for Vaccines, Pneumococcal. Completed, enrolled 225 participants across 9 sites.
Detailed Summary
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines, Pneumococcal
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedJul 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedJul 2, 2008
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18 years ago
Interventions
13-valent pneumococcal conjugate vaccinebiological